A Study to See if Genetic Risk Estimation of Breast Cancer Influences the Use of Preventive Medication

Overview

Información sobre este estudio

The primary aim of this study is to determine if the addition of an individual polygenic risk score (PRS), in addition to the standard National Cancer Institute's Breast Cancer Risk Assessment Tool (BCRAT) or Tyrer-Cuzick (IBIS) score, will aid women at risk of breast cancer in making a decision to take (or not take) medications to prevent breast cancer.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  1. Women > 35 years old and < 75 years old
  2. Women with either of the following:
    1. NCI-BCRAT 5 year risk of ≥ 3% which corresponds to the level in which there is moderate evidence of treatment benefit outweighing risk according to the US Preventative Services Task Force or
    2. Women with a IBIS (Tyrer-Cuzik) score for the 10 year risk of breast cancer of ≥5%
  3. Able to participate in all aspects of the study
  4. Understand and signed the study informed consent

Exclusion Criteria:

  1. Women whose BCRAT falls below the threshold (<3 % 5 year risk) of moderate benefit according to the US Preventative Task Force AND Women whose IBIS score is <5% for the 10 year risk
  2. Women with known BRCA1 and BRCA2 mutations
  3. Women with known contra-indications to Tamoxifen, raloxifene or exemestane
  4. Unable to give informed consent
  5. Prior history of invasive breast cancer or ductal carcinoma in situ
  6. At risk due to prior radiation therapy to the chest

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Sandhya Pruthi, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20273189

Mayo Clinic Footer